TherapeuticsMD, Inc. (NASDAQ:TXMD) Sees Large Drop in Short Interest

TherapeuticsMD, Inc. (NASDAQ:TXMD) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 173,800 shares, a decline of 27.6% from the January 15th total of 240,200 shares. Currently, 1.5% of the company’s stock are sold short. Based on an average trading volume of 289,900 shares, the short-interest ratio is presently 0.6 days.

TherapeuticsMD Price Performance

TXMD opened at $1.03 on Friday. TherapeuticsMD has a 52-week low of $0.70 and a 52-week high of $2.75. The business’s fifty day moving average is $1.11 and its 200-day moving average is $1.44.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.05) earnings per share for the quarter. The business had revenue of $0.55 million for the quarter. TherapeuticsMD had a negative return on equity of 14.08% and a negative net margin of 207.77%.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on TherapeuticsMD in a report on Tuesday, January 14th. They set a “hold” rating on the stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.